Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: A twelve-year "real life" experience

Joint Bone Spine

Volumn 82, Issue 1, 2015, Pages 31-37

  Soubrier, Anne Sophie ^a   Bele Philippe, Peggy ^a   Cortet, Bernard ^a   Ramdane Sebbane, Nassima ^a   Bacle Boutry, Marie Astrid ^a   Lemeunier, Lucie ^a   Flipo, Rene Marc ^a   Paccou, Julien ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Anti TNF ; Drug survival; Methotrexate; Psoriatic arthritis; Safety; Switching

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; GOLD SALT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TIOPRONIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922198207     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.08.001     Document Type: Article

References (43)

1. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71:4-12.
2. Coates L.C., Tillett W., Chandler D., et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 2013, 52:1754-1757.
3. Ash Z., Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012, 71:319-326.
4. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
5. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
6. Mease P.J., Kivitz A.J., Burch F.X., et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712-721.
7. Antoni C.E., Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236.
8. Antoni C.E., Kavanaugh A., van der Heijde D., et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008, 35:869-876.
9. Kavanaugh A., Antoni C.E., Gladman D., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038-1043.
10. Kavanaugh A., Krueger G.G., Beutler A., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505.
11. van der Heijde D., Kavanaugh A., Gladman D.D., et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698-2707.
12. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289.
13. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976-986.
14. Kavanaugh A., Van Der Heijde D., Gladman D., et al. Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL Study. Arthritis Rheum 2010, 62:S812.
15. Glintborg B., Østergaard M., Dreyer L., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63:382-390.
16. Glintborg B., Ostergaard M., Krogh N.S., et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013, 65:1213-1223.
17. Fagerli K.M., Lie E., van der Heijde D., et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013, 72:1840-1844.
18. Fagerli K.M., Lie E., van der Heijde D., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73:132-137.
19. Saad A.A., Ashcroft D.M., Watson K.D., et al. BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010, 49:697-705.
20. Kristensen L.E., Gülfe A., Saxne T., et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008, 67:364-369.
21. Wright V., Moll J.M. Psoriatic arthritis. Bull Rheum Dis 1971, 21:627-632.
22. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
23. Rudwaleit M., Landewé R., van der Heijde D., et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
24. Rudwaleit M., van der Heijde D., Landewé R., et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31.
25. Wendling D., Lukas C., Paccou J., et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine 2014, 81:6-14.
26. Fransen J., Antoni C., Mease P.J., et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65:1373-1378.
27. Braun J., Davis J., Dougados M., et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:316-320.
28. Van den Bosch F., Manger B., Goupille P., et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010, 69:394-399.
29. Gladman D.D., Study Investigators ACCLAIM, Sampalis J.S., et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010, 37:1898-1906.
30. Di Minno M.N., Peluso R., Iervolino S., et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 2013, 65:141-147.
31. Jamnitski A., Symmons D., Peters M.J., et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013, 72:211-216.
32. Ramonda R., Puato M., Punzi L., et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone spine 2014, 10.1016/j.jbspin.2014.02.005.
33. Pertuiset E. Methotrexate in psoriatic arthritis. Joint Bone Spine 2014, 81:107-109.
34. Kavanaugh A., McInnes I.B., Mease P.J., et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013, 72:1777-1785.
35. Mease P., Collier D., Saunders K., et al. Biologic Therapy, time to low disease activity, and effect of mono vs background oral Dmard therapy among psoriatic arthritis patients in a US registry. Ann Rheum Dis 2013, 72:545.
36. Cajigas D., Placensia C., Pascual-Salcedo D., et al. The immunogenicity of biological therapies correlates with clinical efficacy in psoriatic arthritis (PSA) in long-term treatment with infliximab and adalimumab. Ann Rheum Dis 2013, 72:964.
37. Conti F., Ceccarelli F., Marocchi E., et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66:1393-1397.
38. Coates L.C., Cawkwell L.S., Ng N.W., et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008, 67:717-719.
39. Paccou J., Solau-Gervais E., Houvenagel E., et al. Efficacy in current practice of switching between anti-TNFα agents in spondyloarthropathies. Rheumatology 2011, 50:714-720.
40. Iannone F., Notarnicola A., Lopalco G., et al. Different switching rate of anti-TNF-alpha drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. Joint Bone Spine 2014, 10.1016/j.jbspin.2014.01.012.
41. Frazier-Mironer A., Dougados M., Mariette X., et al. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily pratice. Joint Bone Spine 2014, 10.1016/j.jbspin.2014.02.014.
42. Wendling D., Paccou J., Flipo R.M., et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. A nationwide survey. Semin Arthritis Rheum 2011, 3:503-510.
43. Wendling D., Prati C. Paradoxical effects of anti-TNFα agents in inflammatory diseases. Expert Rev Clin Immunol 2014, 10:159-169.